Fairvalue-Calculator Fairvalue-Calculator
EN DE

Acepodia, Inc (6976) Fair Value & Analysis

Healthcare · TW · Market cap 7.1B TWD

Price13.05 TWD
Fair Value6.07 TWD
Upside-53.5%
Quality95/100
Evidence: Low Range 4.01 TWD – 7.59 TWD

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Acepodia, Inc (6976) currently trades at 13.05 TWD, while our model-based Fair Value estimate is 6.07 TWD — implying the stock looks roughly 53.5% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Acepodia, Inc. operates as a clinical stage biotechnology company. The company engages in developing cell therapies with its antibody cell conjugation (ACC) platform technology to address cancer care. It develops AD2C targeting GPC3 for HCC which is in preclinical stage; ACE 1831 targeting CD20 that is in phase 1 clinical trial; The company is based in Grand Cayman, the Cayman Islands.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is Acepodia, Inc (6976) undervalued?
As of Jun 25, 2026, our model estimates a fair value of 6.07 TWD versus a price of 13.05 TWD — about −53% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 6976?
Our 21-model fair value for Acepodia, Inc is 6.07 TWD (as of Jun 25, 2026), built from audited fundamentals. The current price is 13.05 TWD.
What is the quality score of 6976?
Acepodia, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.